الفهرس Only 14 pages are availabe for public view
 |  | from | 151 |  |  |
| | | from | 151 | | |
Abstract
AIM OF THE WORK
Diabetes mellitus is a risk factor for early complications and mortality in patients with peripheral artery disease. Apolipoprotein AI is also suggested to be a marker of increased cardiovascular risk. The coronary artery disease is associated with more than threefold-increased risk in diabetes mellitus. HDL and apo AI, a specific protein of this lipoprotein are risk factors for atherosclerosis. We were investigated the association and interaction between diabetes mellitus, Apo AI gene expression , Apo AI plasma levels and some atherogenic agents . For this purpose, two rat models for these pathologies have been established: a type I diabetic model obtained by streptozotocin injection to rat (STZ-diabetic), followed or not by insulin treatment (experiment 1); a type II diabetic model by feeding rat with a fructose riched diet (F-diabetic), followed or not by rosiglitazone treatment (experiment 2).
This was occurred through study the effect of insulin and rosiglitazone –treatment on:
1.Gene expression of Apo AI in liver tissues .
2.Plasma Apo AI concentration.
3-Heart and liver tissues glycogen.
4- Blood glucose.